1. Australia Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Genetic Technologies Limited

Genetic Technologies Limited

GTG.AX
Genetic Technologies LimitedAU flagAustralian Securities Exchange
0.04
AUD
- -
- -
5.67MMarket Cap
Genetic Technologies Limited
GTG.AX
(Australian Securities Exchange)

Recent

price

0.04

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
2.85
1.2
1.06
0.75
0.67
0.74
0.18
0.04
0.02
0.01
- -
- -
- -
0.07
0.09
0.06
- -
Revenue per Share
-1.96
-2.29
0.21
-1.07
-1.84
-1.64
-0.77
-0.46
-0.37
-0.22
-0.23
-0.15
-0.08
-0.08
-0.12
-0.09
- -
Basic EPS, GAAP
-1.28
-1.38
0.48
-0.02
-1.5
-1.79
-0.86
-0.44
-0.01
-0.23
- -
- -
-0.01
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
3.06
0.98
1.13
2.13
0.33
-0.34
1.24
0.32
0.2
-0.04
-0.15
0.1
0.12
0.05
0.05
-0.02
- -
Book Value per Share
2.38
0.96
1.18
2.63
0.88
0.11
1.59
0.61
0.47
0.19
0.06
0.34
0.25
0.12
0.07
- -
- -
Tangible Book Value per Share
4
4
4
5
5
6
11
18
23
24
28
42
85
92
101
132
- -
Basic Weighted Avg Shares
11
5
5
4
3
5
2
1
1
- -
- -
- -
- -
7
9
8
- -
Sales/Revenue/Turnover
-72.3
-206
22.8
-298.55
-276.16
-215.88
-484.88
-1,038.38
-1,527.1
-3,316.52
-27,581.59
-44,506.85
-6,802.95
-134.02
-130.91
-159.3
- -
Operating Margin (%)
4
4
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
- -
Depreciation Expense
-8
-9
1
-5
-9
-10
-9
-8
-8
-5
-6
-6
-7
-7
-12
-12
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-68.82
-190.09
19.8
-143.25
-275.33
-221.84
-437.9
-1,025.84
-1,620.78
-2,887.06
-25,253.91
-63,815.64
-5,870.91
-104.95
-135.28
-156.78
- -
Profit Margin (%)
6
2
4
8
- -
2
18
11
10
5
2
14
21
11
7
-1
- -
Working Capital
- -
- -
- -
- -
- -
3
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
14
6
7
14
6
2
19
12
11
5
2
14
22
16
11
2
- -
Total Equity
- -
- -
16.21
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
20.51
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-47.67
-114.93
20.41
-68.48
-152.25
- -
- -
-84.21
-162.19
- -
- -
- -
-97.19
-92.42
-245.85
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'25
ST Debt
- -
1
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
101
- -
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'25
Total Current Assets
- -
4
- -
Cash, Cash Equivalents & STI
- -
1
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
4
- -
Payables & Accruals
- -
2
- -
ST Debt
- -
1
- -
Deferred Revenue
- -
1
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
137.58%
120.91%
-83.6%
Free Cash Flow
382.94%
351.94%
87.82%
Net Income, GAAP
4.32%
15.64%
2.27%
Sales/Revenue/Turnover
631.12%
1,322.67%
-11.76%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
9
2024
- -
- -
- -
- -
8
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.12
2024
- -
- -
- -
- -
-0.09
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Invitae Corporation (NVTA)
Integrative Health Technologies, Inc. (IHTI)
Cellbxhealth PLC (ANPCF)
Bionano Genomics, Inc. (BNGO)
Wellfully Limited (WFL.AX)
Mainz Biomed B.V. (MYNZ)
Business
Genetic Technologies Limited (Ticker: GTG.AX) is a biotechnology company specializing in genetic testing and molecular diagnostics. The company’s primary products and services include genetic testing kits and assays designed to assess genetic predispositions to various health conditions, including cancer and other hereditary diseases. Genetic Technologies offers a portfolio of proprietary genetic tests, such as the OncoE6™ Cervical Test and other cancer-related molecular diagnostic tools, targeting healthcare providers, research institutions, and pharmaceutical companies. The company operates primarily in Australia and internationally, focusing on markets with growing demand for precision medicine and genetic screening solutions. Founded in 1994 and headquartered in Australia, Genetic Technologies Limited has recently undergone strategic expansions, including collaborations and partnerships to enhance its genetic testing capabilities and broaden the commercial reach of its proprietary products. Notably, in the last 1-2 years, the company has pursued new alliances and product launches to strengthen its presence in the molecular diagnostics field, targeting growth in both clinical and research applications. These recent developments illustrate Genetic Technologies’ commitment to advancing personalized healthcare through innovative genetic testing services. The company conducts business in the biotechnology and healthcare sectors, serving genetic testing laboratories, hospitals, research organizations, and pharmaceutical firms globally. It maintains active research and development efforts to introduce next-generation genetic assays and diagnostic technologies. Genetic Technologies Limited is publicly traded on the Australian Securities Exchange under the ticker GTG.AX and continues to focus on expanding its commercial partnerships and product offerings within the genetic testing and molecular diagnostics industry.